TCM
PDLI

Traynor Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Traynor Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15,000
Closed -$51K – 189
2017
Q3 		$51K Hold
15,000
– – 0.02% 163
2017
Q2 		$36K Hold
15,000
– – 0.02% 159
2017
Q1 		$32K Buy
+15,000
New +$33.2K 0.02% 153
2016
Q3 		– Sell
-28,534
Closed -$88K – 140
2016
Q2 		$88K Buy
+28,534
New +$95.2K 0.07% 124

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Traynor Capital Management's PDLI Position: Q4 2017 in Review

Traynor Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2017, closing a stake of 15,000 shares — an estimated $51K sold.

Traynor Capital Management first reported a position in PDLI in Q2 2016 and held it in 4 quarters. The position peaked at $88K in Q2 2016. 187 funds tracked by Wall St. Rank hold PDLI as of Q4 2017.

  • Traynor Capital Management reported no remaining PDL BioPharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Traynor Capital Management sold 15,000 PDL BioPharma, Inc. shares in Q4 2017, an estimated $51K.
  • Traynor Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2016 and held it in 4 quarters.
  • Traynor Capital Management's PDL BioPharma, Inc. position peaked at $88K in Q2 2016.
  • 187 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2017.

Based on Traynor Capital Management's 13F filing for Q4 2017, filed 1 Feb 2018.